Table 1.
Summary of studies performed with NB‐360 in mouse models
| Mouse model | Age at onset of treatment (months) | Treatment duration (months) | Daily dose | Main endpoints | Reference |
|---|---|---|---|---|---|
| APP51/16, female | 14.5 | 1.5 | 100 μmol·kg−1 (45 mg·kg−1) | Aβ deposition and neuroinflammation | Neumann et al. (2015) |
| APP23, female | 17.5 | 3 | 30 μmol·kg−1 (14.5 mg·kg−1) | Brain microhaemorrhages | Beckmann et al. (2016) |
| APP23, male | 15 | 6.5 | 0.5 g·kg−1 in chow | Mouse tau in CSF | Schelle et al. (2017) |
| APPPS1, male and female | 1.5 | 6 | 0.5 g·kg−1 chow | Mouse tau in CSF | Schelle et al. (2017) |
| APPPS1, male | 1.5 | 6 | 0.5 g·kg−1 chow | Mouse neurofilament light chain in CSF | Bacioglu et al. (2016) |
| APP23xPS45, female | 6–7 | 1.5 | 0.25 g·kg−1 chow | Neuronal hyperactivity and slow brain waves | Keskin et al. (2017) |
| APPPS1xVGLUT1 | 4 | 3 | 0.25 g·kg−1 chow | Aβ plaque kinetics | Peters et al. (2018) |
| APP tg‐SweArc | 10 | 3 | 0.5 g·kg−1 chow | PET of Aβ protofibrils | Meier et al. (2018) |
| SEZ6+/+ and SEZ6−/− × GFP, male and female | 3–4 | 0.75 | 0.25 g·kg−1 chow | Spine density and dynamics | Zhu et al. (2018) |
| C57/Bl6J | 4–5 | 2 | 100 μmol·kg−1 (45 mg·kg−1) | Hair depigmentation | Shimshek et al. (2016) |
Note: Aβ: amyloid‐β.